Evidence map›Paper›PMID 36076479›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022

Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection.

Jan Bińkowski, Olga Taryma-Leśniak, Karolina Łuczkowska, Anna Niedzwiedź, Kacper Lechowicz, Dominik Strapagiel, Justyna Jarczak, Veronica Davalos, Aurora Pujol, Manel Esteller and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Jan BińkowskiIndependent Clinical Epigenetics Laboratory, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Olga Taryma-LeśniakIndependent Clinical Epigenetics Laboratory, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Karolina ŁuczkowskaDepartment of General Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Anna NiedzwiedźDepartment of Internal Medicine and Diabetology with the Subdepartment of Endocrinology,Independent Public Regional Hospital in Szczecin, Szczecin, Poland.
Kacper LechowiczDepartment of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Dominik StrapagielBiobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Justyna JarczakBiobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland; Laboratory of Molecular Basis of Behavior, Nencki Institute of Experimental Biology, Polish Academy of Science, Warsaw, Poland.
Veronica DavalosCancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
Aurora PujolNeurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain; Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
Manel EstellerCancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.
Katarzyna KotfisDepartment of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Bogusław MachalińskiDepartment of General Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Miłosz ParczewskiDepartment of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Tomasz K WojdaczIndependent Clinical Epigenetics Laboratory, Pomeranian Medical University in Szczecin, Szczecin, Poland; Department of Biomedicine, Aarhus University, Aarhus, Denmark. Electronic address: tomasz.wojdacz@pum.edu.pl.
Pomeranian Medical University · PLInstitut d'Investigació Biomédica de Bellvitge · ESInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLJosep Carreras Leukaemia Research Institute · ESUniversitat de Barcelona · ESUniversity of Łódź · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that methylation changes identified in blood cells of COVID-19 patients have a potential to be used as biomarkers of SARS-CoV-2 infection outcomes. However, different studies have reported different subsets of epigenetic lesions that stratify patients according to the severity of infection symptoms, and more importantly, the significance of those epigenetic changes in the pathology of the infection is still not clear. We used methylomics and transcriptomics data from the largest so far cohort of COVID-19 patients from four geographically distant populations, to identify casual interactions of blood cells' methylome in pathology of the COVID-19 disease. We identified a subset of methylation changes that is uniformly present in all COVID-19 patients regardless of symptoms. Those changes are not present in patients suffering from upper respiratory tract infections with symptoms similar to COVID-19. Most importantly, the identified epigenetic changes affect the expression of genes involved in interferon response pathways and the expression of those genes differs between patients admitted to intensive care units and only hospitalized. In conclusion, the DNA methylation changes involved in pathophysiology of SARS-CoV-2 infection, which are specific to COVID-19 patients, can not only be utilized as biomarkers in the disease management but also present a potential treatment target.

Indexed as

COVID-19BiomarkersEpigenesis, GeneticHumansInterferonsSARS-CoV-2BiomarkersInterferonsCoronavirusCOVID-19DNA methylationEpigeneticsSARS-CoV-2

Identifiers

PMID36076479
PMCPMC9271528
OpenAlexW4285013001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.